Mechanism of action In the setting of HLH, over-secretion of IFN-γ is thought to contribute to the pathogenesis of the disease.<unk>  binds and neutralizes IFN-γ, preventing it from inducing pathological effects. Pharmacokinetics Like other antibody-based medications, which are made of amino acid chains called polypeptides,<unk>  is broken down into smaller peptides via the body's normal catabolism.
Emapalumab
Olaratumab
Ustekinumab
Evolocumab
Anifrolumab
Dupilumab
Sarilumab
Burosumab